NCT07065071

Mentalization-Based Therpay With Older Adults

Completed Last updated 5 March 2026

What this trial tests

trial testing Mentalization-Based Therapy in Mentalisation in 3 participants. Completed in 22 January 2026.

Timeline

1 April 2025

Primary endpoint
22 January 2026

22 January 2026

Quick facts

Lead sponsor	University of Nottingham
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3
Start date	1 April 2025
Primary completion	22 January 2026
Estimated completion	22 January 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

• Mentalization-Based Therapy

Conditions studied

• Mentalisation — all drugs for Mentalisation →
• Mentalization — all drugs for Mentalization →
• Later Life — all drugs for Later Life →
• Older Adults — all drugs for Older Adults →

Sponsor

University of Nottingham

Who can join

60 and older, any sex, with Mentalisation or Mentalization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators would like to find out if Mentalization-Based Therapy (MBT) is effective for people aged 60+ who struggle in relationships. The study aims to understand whether MBT helps older people to build better relationships and feel better about themselves. There is currently no research with people over 60 and MBT, yet MBT is being offered to the older adult population by NHS trusts throughout the UK without evidence for its effectiveness. As well as developing knowledge about how MBT can help at this point in life, the study aims to improve the quality of care offered.

MBT targets mentalization, which is the ability to make sense of one's own and other people's thoughts, feelings, actions and beliefs. Current research suggests that the ability to mentalize changes over the lifespan and may be influenced by many factors, some of which are specific to later life. For example, changes in relationships during later life and biological changes in the brain may impact mentalization systems.

The investigators would also like to understand what difficulties MBT may be effective for in later life. The diagnosis of borderline personality disorder (BPD), which MBT was developed to treat, was, until recently, assumed to disappear with age. However, growing evidence suggests that symptoms change, rather than disappear.

Given these unknowns, the study will use a Hermeneutic Single-Case Efficacy Design (HSCED). Up to six participants, up to six people who know the participants, and clinicians delivering the MBT interventions will be recruited. Data in the form of questionnaires, self-report and therapy documents will be gathered, and everyone will be interviewed. For each participant, the data will be used to compile both an affirmative (yes, MBT was effective) case, and a sceptic case (no, MBT was not effective). Cases will then be reviewed by an adjudication panel comprising one service user expert by experience, one MBT expert and one expert in another therapeutic modality. For each case, each expert will decide if the affirmative or sceptic case was more likely. Finally, findings will be synthesised and used to draw conclusions about the effectiveness of MBT.

The HSCED lends itself to theory-building, as it gathers in-depth data from individuals and facilitates comparison within and between cases. Further, participants' contribution to their own 'rich case record' through change interviews recognises people as taking an active role in their own healing.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.